UK markets open in 25 minutes
NIKKEI 225
37,552.16 +113.55 (+0.30%) HANG SENG
16,790.11 +278.42 (+1.69%) CRUDE OIL
83.02 +0.17 (+0.21%) GOLD FUTURES
2,315.90 -30.50 (-1.30%) DOW
38,239.98 +253.58 (+0.67%) Bitcoin GBP
53,920.05 +146.33 (+0.27%)
AbbVie Inc. (ABBV)
NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 166.41 |
| Open | 167.68 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's range | 166.92 - 169.59 |
| 52-week range | 130.96 - 182.89 |
| Volume | |
| Avg. volume | 5,645,112 |
| Market cap | 297.274B |
| Beta (5Y monthly) | 0.56 |
| PE ratio (TTM) | 61.72 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 6.20 (3.69%) |
| Ex-dividend date | 12 Apr 2024 |
| 1y target est | N/A |
- Zacks
AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?
Investor focus is likely to be on the sales of AbbVie's (ABBV) blockbuster immunology drugs Rinvoq and Skyrizi when it reports first-quarter results.
- Investor's Business Daily
The Bad News Heading Into AbbVie's First-Quarter Earnings Report
AbbVie stock has slumped 9% off its record high in March and is facing increasingly steep competition for its biggest moneymaker, Humira.
- Zacks
Earnings Preview: AbbVie (ABBV) Q1 Earnings Expected to Decline
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
© 2024 Yahoo. All rights reserved.